NewsBlazeIN – Lifestyle
Author:
Pharvaris N.V.
Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference
April 20, 2026
Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
April 2, 2026
Evidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Hereditary Angioedema Attacks Published Back-to-Back in The Lancet Haematology
March 20, 2026
Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Allergy & Immunology
March 11, 2026